- Home
- SKYE vs BRW Comparison
SKYE vs BRW Comparison
Compare SKYE & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKYE | BRW |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 308.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | BRW |
|---|---|---|
| Price | $0.72 | $6.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | ★ 448.8K | 222.1K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $7.15 |
| 52 Week High | $5.75 | $8.30 |
Technical Indicators
Market Signals| Indicator | SKYE | BRW |
|---|---|---|
| Relative Strength Index (RSI) | 23.91 | 36.64 |
| Support Level | $0.76 | $6.92 |
| Resistance Level | $0.95 | $7.01 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.00 | 22.88 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.